Skip to content
Sacrosidase
Sucraid (sacrosidase) is an enzyme pharmaceutical. Sacrosidase was first approved as Sucraid on 1998-04-09. It is used to treat congenital abnormalities and digestive system diseases in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
digestive system diseasesD004066
hereditary congenital and neonatal diseases and abnormalitiesD009358
Trade Name
FDA
EMA
Sucraid
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Sacrosidase
Tradename
Proper name
Company
Number
Date
Products
SucraidsacrosidaseQol MedicalN-20772 RX1998-04-09
2 products
Labels
FDA
EMA
Brand Name
Status
Last Update
sucraidBiologic Licensing Application2020-04-15
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
congenital abnormalitiesEFO_0003915D000013Q89.9
digestive system diseasesEFO_0000405D004066K92.9
Agency Specific
FDA
EMA
Expiration
Code
sacrosidase, Sucraid, QOL Medical, LLC
2105-04-09Orphan excl.
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A16: Other alimentary tract and metabolism products in atc
— A16A: Other alimentary tract and metabolism products in atc
— A16AB: Enzymes for alimentary tract and metabolism
— A16AB06: Sacrosidase
HCPCS
No data
Clinical
Clinical Trials
62 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C801061—115
Ovarian neoplasmsD010051EFO_0003893C56564——12
Fallopian tube neoplasmsD005185355—112
Castration-resistant prostatic neoplasmsD064129233——7
Prostatic neoplasmsD011471C61241——6
Ovarian epithelial carcinomaD000077216—23—16
Peritoneal neoplasmsD010534133——6
AdenocarcinomaD000230—21——3
Large cell carcinomaD018287——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C5033———6
Endometrial neoplasmsD016889EFO_000423014———4
Small cell lung carcinomaD05575213———3
Pancreatic neoplasmsD010190EFO_0003860C2513———3
CarcinosarcomaD00229611———2
Uterine cervical neoplasmsD002583—2———2
Biliary tract neoplasmsD001661C24.912———2
Non-small-cell lung carcinomaD00228912———2
Urologic neoplasmsD014571C64-C6812———2
Malignant mesotheliomaD000086002—1———1
Show 15 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Female genital neoplasmsD0058331————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSACROSIDASE
INNsacrosidase
Description
Sacrosidase (trade name Sucraid) is a medication used to replace sucrase in people lacking this enzyme. It is available as an oral solution. Sucraid is approved by the U.S. Food and Drug Administration (FDA) for the therapy of the genetically determined sucrase deficiency that is part of the Congenital Sucrase-Isomaltase Deficiency (CSID). Sacrosidase assists in the breakdown of sugar/sucrose into simpler forms and is useful for the relief of gastrointestinal symptoms that are associated with CSID.
Classification
Enzyme
Drug classenzymes
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID85897-35-4
RxCUI214817
ChEMBL IDCHEMBL1201487
ChEBI ID—
PubChem CID—
DrugBankDB06760
UNII ID8A7F670F2Y (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 49 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
6,496 adverse events reported
View more details